Diseases & Disorders
(G80)
990 on File
NORTH AMERICAN SOCIETY FOR THE STUDY OF CELIAC DISEASE INC
Financial strength (30%)
55/100
Reliability (20%)
50/100
Effectiveness (25%)
61/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2025
$69K
Total Revenue
$179K
Total Expenses
$0
Net Assets
N/A
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
97.4%
Fundraising Efficiency
N/A
Operating Reserve
0.00x
Liability-to-Asset
N/A
Revenue Diversification
87.0%
Compared with Peers
FY 2025
Compared with 693 similar organizations
(United States, Diseases & Disorders, $100K–$1M in expenses), FY 2025.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
97.4% | 83.5% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
0.0 mo | 11.9 mo |
P10P90
|
Bottom quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
87.0% | 93.4% |
P10P90
|
Above median |
|
Revenue growth
Year over year revenue growth
|
5.9% | 7.5% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
-3.7% | 8.1% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
-159.5% | 4.2% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2025 | $69K | $179K | $0 | 97.4% | — |
| 2024 | $65K | $186K | $110K | 97.8% | — |
| 2023 | $102K | $72K | $231K | 54.4% | — |
| 2022 | $167K | $47K | $201K | 95.5% | — |
| 2021 | $64K | $34K | N/A | — | 1 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.